CBAY News and Press, CymaBay Therapeutics Inc. From 09/10/23

2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...

2023-09-08 15:00:57 ET More on the markets The Unemployment Rate Just Signaled That A Recession May Occur Within The Next 6 Months High Yield Signal Does Not Align With Bearish Outlook For SPY SPY: The Calm Before The Storm Bulls vs. Bears: SA analysts weigh ...

2023-09-08 11:59:06 ET Shares of CymaBay Therapeutics (NASDAQ: CBAY) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday. The continued momentum is a result of CymaBay's announcement yesterday of positive top-line resu...

2023-09-08 11:33:50 ET Summary CymaBay's stock jumped nearly 10% after positive Phase 3 data for seladelpar in Primary Biliary Cholangitis (PBC). The market opportunity for seladelpar may not support peak sales of over $300 million, and the stock may have already reached its ceili...

2023-09-08 10:00:08 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

2023-09-07 17:10:58 ET Gainers: Smith & Wesson Brands  ( SWBI ) +11% . CymaBay Therapeutics ( CBAY ) +5% . DocuSign ( DOCU ) +5% . Ocular Therapeutix ( OCUL ) +4% . CorMedix  ( CRMD ) +4% . Losers: Altisourc...

2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...

CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis PR Newswire Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7%...

NEWARK, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will host an investor call on Thursday,...

NEWARK, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees betw...